Monopar Q2 FY26 net loss widens to $5.3 million

• Monopar posted a Q2 net loss of $5.3 million, or $0.62 per share, widening from a $2.5 million loss, or $0.35 per share.
• R&D expense more than doubled to $4.77 million, driven by higher contractor and consulting costs.
• G&A expense rose 24.83% to $1.88 million, reflecting higher personnel and contractor spending.
• Cash, cash equivalents and investments totaled $134.3 million; runway expected through at least Dec. 31, 2027.
• Rolling FDA NDA submission started for ALXN1840 in Wilson disease; Rare Pediatric Disease designation granted, supporting potential priority review voucher.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.